Warfarin: risk factors for bleeding
Evidence-based neurology checklist on warfarin: risk factors for bleeding: Demographic risks During the first year of treatment Elderly subjects older than 65 years Vitamin K epoxide reductase complex (VKORC) alleles CYP2C9 polymorphisms Co-morbidity risks Drug-related risks Blood test related risks
Demographic risks
- During the first year of treatment
- Elderly subjects older than 65 years
Vitamin K epoxide reductase complex (VKORC) alleles
CYP2C9 polymorphisms
Co-morbidity risks
Drug-related risks
Blood test related risks
References
- Bal S, Ojha P, Hill MD. Stroke prevention treatment of patients with atrial fibrillation: old and new. Curr Neurol Neurosci Rep 2011; 11:15-27.
- Broukhim M, Halperin JL. Stroke prevention in the high-risk atrial fibrillation patient: medical management. Curr Cardiol Rep 2011; 13:9-17.
- Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713-719.
- Kirchhof P, Lip GYH, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options- a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012; 14:8-27.
- Moyer TP, O'Kane DJ, Baudhuin LM, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009; 84:1079-1094.
- And 2 more. Subscribe to see the full list
